ARID1B | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

35 results for “ARID1B”

Trials

View all 23 →

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

100,000 participants · First posted Nov 10, 2010

Not yet recruiting

TR115 in ARID1A-Mutated Advanced Solid Tumors

50 participants · First posted Aug 28, 2026

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

25 participants · First posted Jul 24, 2024

Drugs

Selective ARID1B(Foghorn Therapeutics)

Selective ARID1B protein degrader (cancer)

JARID1A/1B inhibitors (Celgene)

Organizations

Aridis Pharmaceuticals, Inc.

United States

News

Foghorn Therapeutics Reports Breakthrough Progress in Selective ARID1B Degrader for Cancer Treatment

Foghorn Therapeutics Advances Oncology Programs Targeting Chromatin Dysregulation

Foghorn Therapeutics Secures $50 Million Financing to Advance First-in-Class Cancer Pipeline

Page 1 of 4